Paris Brain Institute at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Paris Brain Institute brings 4 presentations to ESGCT 2026 in Hamburg. Its work centres on AAV gene therapy for brain disease, including intravenous treatment for mucopolysaccharidosis types IIIA and IIIB in mouse and dog models and an approach to amyotrophic lateral sclerosis. A further strand harmonises qPCR for measuring where AAV ends up across species.
| Organization | ESGCT 2026 Attendance |
|---|---|
Paris Brain Institute Paris, France | |
Neuroscience research institute at the Pitié-Salpêtrière hospital; its GENOV unit develops gene and cell therapies for adult and childhood neurodegenerative diseases. | Poster Wed Oct 28 1:30pm–3:30pm Enhanced anti-Aß immunotherapy using AAV-delivered nanobodies in an AD mouse model Poster Wed Oct 28 1:30pm–3:30pm Robust AAV biodistribution assessment in preclinical studies using a harmonized qPCR workflow and universal reference gene in fresh and fixed tissues across species. Poster Thu Oct 29 2:00pm–4:00pm Gene therapy of Amyotrophic Lateral Sclerosis Poster Thu Oct 29 2:00pm–4:00pm Intravenous AAV gene therapy for mucopolysaccharidosis type IIIA and IIIB in mouse and canine model of the pathology – towards clinical translation |
Instantly find 20 buyers from Paris Brain Institute
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction